Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline

Rasagiline is a selective and irreversible inhibitor of monoamine oxidase type B with neuroprotective effect, indicated for the management of Parkinson’s disease. The aim of this work was to evaluate the impact of seven <i>CYP1A2</i> alleles and of 120 additional variants located in other CYP enzyme...

Descrición completa

Detalles Bibliográficos

Principais autores:	Pablo Zubiaur, Miriam Matas, Samuel Martín-Vílchez, Paula Soria-Chacartegui, Gonzalo Villapalos-García, Laura Figueiredo-Tor, Sofía Calleja, Marcos Navares-Gómez, Alejandro de Miguel, Jesús Novalbos, Gina Mejía-Abril, Sergio Luquero-Bueno, Manuel Román, Dolores Ochoa, Francisco Abad-Santos
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2022-09-01
Series:	Pharmaceutics
Assuntos:	rasagiline Parkinson’s disease pharmacogenetics pharmacokinetics precision medicine
Acceso en liña:	https://www.mdpi.com/1999-4923/14/10/2001
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!